Cubist Stressing Cidecin Short Duration Of Therapy; NDA Has Priority Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cubist plans to highlight a shorter duration of therapy with Cidecin (daptomycin) to differentiate the pending antibiotic from currently marketed agents for Gram-positive infections.